Cargando…
Role and clinical utility of pramipexole extended release in the treatment of early Parkinson’s disease
The aim of this article is to provide a short review of the most relevant pharmacological and clinical data on pramipexole extended release (ER) as well as to address the clinical utility and potential advantages of a once-daily formulation especially in the treatment of early Parkinson’s disease (P...
Autores principales: | Hametner, Eva-Maria, Seppi, Klaus, Poewe, Werner |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324991/ https://www.ncbi.nlm.nih.gov/pubmed/22500116 http://dx.doi.org/10.2147/CIA.S11829 |
Ejemplares similares
-
Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release
por: Hauser, Robert A., et al.
Publicado: (2014) -
Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease
por: Hauser, R A, et al.
Publicado: (2014) -
P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease
por: Hauser, Robert A., et al.
Publicado: (2022) -
Pramipexole and its Extended Release Formulation for Parkinson’s Disease
por: Fishman, Paul S.
Publicado: (2011) -
Pramipexole Extended Release: A Novel Treatment Option in Parkinson's Disease
por: Eisenreich, Wolfram, et al.
Publicado: (2010)